IPO News
Prev Next
As on Jan 23, 2017 12:00 AM Your results on : IPO News    
BSE IPO subscribed 47% on day 1
23-Jan-2017 (16:48)
BSE raises Rs 373 crore from anchor investors
23-Jan-2017 (10:29)
BSE IPO to commence on 23 January 2017
17-Jan-2017 (09:25)
Laurus Labs shines on debut
19-Dec-2016 (16:06)
Sheela Foam makes a stellar debut
09-Dec-2016 (16:23)
Laurus Labs' IPO sees strong response from investors
09-Dec-2016 (10:40)

Laurus Labs' initial public offer (IPO) saw strong response from investors. The issue received bids for 10.01 crore shares compared with 2.19 crore shares on offer. The IPO was subscribed 4.57 times. The qualified institutional buyers (QIBs) category was subscribed 10.54 times. The non-institutional investors' category was subscribed 3.58 times. The retail investors category was subscribed 1.67 times.

The bidding for the IPO opened on 6 December and closed yesterday, 8 December 2016. The price band for the IPO was fixed at Rs 426 to Rs 428 per share.

The IPO comprised of fresh issue of Rs 300 crore and the offer for sale of 2.41 crore shares by the selling shareholders. The selling shareholders are Aptuit, Bluewater, FIL Capital Management and FIP (acting through its trustee FIL Capital Advisors). The proceeds of the offer for sale shall be received by the selling shareholders, and the company will not receive any proceeds from the offer for sale.

The IPO committee of the board of directors of the company at a meeting held on 5 December 2016, allocated 92.38 lakh shares to 25 anchor investors at Rs 428 per share, the higher price of IPO price band aggregating Rs 395.40 crore.

The company proposes to utilise the net proceeds from the fresh issue towards the pre-payment of term loans and the general corporate purposes. In addition the company expects to receive the benefits of listing of the shares on the stock exchanges, enhancement of the company's brand name and creation of a public market for shares.

For the six months ended 30 September 2016, Laurus Labs reported consolidated net profit of Rs 75.10 crore on total revenue of Rs 941.78 crore.

Laurus Labs is a leading research and development (R&D) driven pharmaceutical company, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. The company also manufactures APIs in oncology and other therapeutic areas. The company operates in four business lines: generics-APIs, generics-FDFs, synthesis and ingredients.

Laurus Labs' IPO subscribed 4.43 times
08-Dec-2016 (16:34)
Laurus Labs' IPO subscribed 61%
07-Dec-2016 (18:22)
Laurus Labs' IPO subscribed 27% on day one
06-Dec-2016 (16:33)
Laurus Labs raises Rs 395.40 crore from anchor investors
06-Dec-2016 (09:54)
Laurus Labs IPO opens on 6 December
02-Dec-2016 (12:16)
Sheela Foam IPO's QIB category subscribed 14.51 times
02-Dec-2016 (11:01)
Sheela Foam IPO subscribed 5.01 times
01-Dec-2016 (17:14)
Sheela Foam IPO subscribed meager 6% by day two
30-Nov-2016 (16:50)
Connect with us :   
About us
Our Services
Core Values
Investor Relations
Product & Services
Institutional Broking
Clearing Services
Trade & Products
Globe Connect Pro
Globe Trade Smart
Globe Connect Mobile/Tablet
Globe News Connect
Back Office
Back Office
KYC/KDC Status
Mutual Fund
RMS Policy
Download Forms
Useful Links
Exchange Holidays
Policies, Procedures, Rights, Obligations and RDD
Guidance Note on FATCA and CRS May 2016
Right and Obligation, RDD, Guidance Note in Vernacular Language
In case of any grievances pleae write to (For Trading) (For DP) (For PMS) (For Commodities)
SEBI Regn. No. NSE.:INB/INF/INE 230663732, TM No.:06637, Clearing No.- M50302 | SEBI Regn. No. BSE.:INB/INF/INE 010663731, Clearing No.- 3179 | SEBI Regn No. MSEI :INB/F 260663738, INE 260663732, TM Code-1004, Clearing Member Code- 4 | USE SEBI Regn no. - INE 270663732 , CM code: 06637 | SEBI Regn for DP : IN-DP-NSDL-97-99, NSDL- DP ID: IN300966, CDSL DP ID: 12020600 | Research Analysts Regn No. INH100001187 | PMS Regn No. INP000002361
* Through subsidiary Globe Commodities Ltd. --> Commodity Membership No.: NCDEX- FMC Regn. No. NCDEX/TCM/CORP/0004, TM Code-00012 | MCX- FMC Regn. No. MCX/TCM/CORP/0628, CM Code-8550 | ICEX- FMC Regn. No. ICEX/TCM/CORP/0011, TM Code- 1009 | NMCE- FMC Regn. No. NMCE/TCM/CORP/0018, TM Code-CL0111 | ACE - FMC Registration no.- ACEL/TCM/CORP/0163, TM code- 4001 | UCX FMC Regn. No.: UCX/TCM?CORP/0014, TM Code- 10014 | NCDEX Spot Exchange Membership no.- NCDEXSPOT-CR-07-10011
** Through step in subsidiary Globe Comex International DMCC --> DGCX **TM Id.1064, CM Id.3064*
"We also do Pro-Account trading in Commodity Segment.."
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Attention Investors:
"Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your Stock Brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors"
"Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors."
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
© 2013 Globe Capital Market Limited. All rights reserved
Designed, Developed and Content powered by C-MOTS Infotech (ISO 9001:2008 Certified) Privacy Policy Disclaimer Terms and Conditions